Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023
- Written by PR Newswire
SHANGHAI, July 26, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that clinical trial data from phase I/II study for advanced solid tumor of Nectin-4-targeting ADC (9MW2821), and phase III study of Long-Acting Recombinant Human Serum Albumin/Human Granulocyte-Colony...
Read more: Mabwell to Present Clinical Trial Data of 2 Programs at ESMO Congress 2023














